Recruiting PHASE4 INTERVENTIONAL 2-arm NCT07133438

Mecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion Treatment

Mecobalamin Combined With Anti-VEGF Intravitreal Injection for Treatment Retinal Vein Occlusion: a Double-blind Randomized Controlled Trial

Sponsor: First Affiliated Hospital of Chongqing Medical University

Conditions Retinal Vein Occlusion (RVO)

Interventions Anti-VEGF drug Mecobalamin 5 MG Placebo

Updated 2 times since 2025 Last updated: Feb 24, 2026 Started: Aug 1, 2025 Primary completion: May 31, 2027 Completion: Jul 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07133438, this PHASE4 trial focuses on Retinal Vein Occlusion (RVO) and remains actively recruiting participants. Sponsored by First Affiliated Hospital of Chongqing Medical University, it has been updated 2 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

2 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting
Sep 2025 — Feb 2026 [monthly]

Not Yet Recruiting PHASE4

First recorded

Aug 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

First Affiliated Hospital of Chongqing Medical University

Data source: First Affiliated Hospital of Chongqing Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chongqing, China